French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...

The proposal from PAI Partners, challenging a US bidder, is the latest twist in a battle to win a 50% stake in Opella, the ...

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...